Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clopidogrel vs Aspirin + Low-dose Rivaroxaban in Atherosclerotic Cardiovascular Disease
NCT07796217Phase 4Recruiting
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Nov 2023
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 4 trial of rivaroxaban, clopidogrel in coronary artery disease (CAD), peripheral artery disease (PAD), sponsored by Seoul National University Bundang Hospital. Started Nov 2023; status: recruiting.
02
Drugs
rivaroxabanclopidogrel
03
Conditions
coronary artery disease (CAD)peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT07796217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07796217.